240 recruiting, 135 completed, 134 active not recruiting, 78 terminated. 417 Phase 2, 303 Phase 1, 81 Phase 3, 32 Not applicable, 6 Early Phase 1.
Follow this drug Literature Review of venetoclax trials Research Report on venetoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 132 | 2026-11-27 | 2026-09-09 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia venetoclax, chidamide, and chiglitazar sodium (VCC) - Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-11-11 | 2026-08-24 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy IPN60340 + azacitidine + venetoclax, Placebo + azacitidine + venetoclax - Acute Myeloid Leukaemia (AML), Acute Myeloid Leukaemia | Phase 2 / Phase 3 | Not yet recruiting | Ipsen | 540 | 2026-11-01 | 2026-09-10 |
| The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations Selinexor - Myeloid Tumors | Not applicable | Not yet recruiting | Bing Han | 30 | 2026-11-01 | 2026-06-08 |
| Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML Liposome Mitoxantrone, Venetoclax, Azacitidine - Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2026-10-30 | 2026-09-18 |
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients CLN-049, Azacitidine, Venetoclax - AML (Acute Myeloid Leukemia) | Phase 1 | Not yet recruiting | Cullinan Therapeutics Inc. | 90 | 2026-10-15 | 2026-07-23 |
| Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL olverembatinib, Venetoclax, Inotuzumab Ozogamicin (IO) - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 22 | 2026-10-12 | 2026-09-25 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
Showing 20 of 714. Sign in to see all of them.
Leukemia, Myeloid, Acute (327) · Leukemia, Lymphocytic, Chronic, B-Cell (112) · Myelodysplastic Syndromes (70) · Recurrence (60) · Leukemia (43) · Neoplasms (42) · Lymphoma, Non-Hodgkin (41) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Lymphoma, Mantle-Cell (33) · Multiple Myeloma (28) · Leukemia, Myelomonocytic, Chronic (27) · Lymphoma, Large B-Cell, Diffuse (27) · Lymphoma, Follicular (22) · Lymphoma (21) · Hematologic Neoplasms (20)
M.D. Anderson Cancer Center (69) · AbbVie (68) · Institute of Hematology & Blood Diseases Hospital, China (36) · National Cancer Institute (NCI) (35) · The First Affiliated Hospital of Soochow University (22) · Hoffmann-La Roche (17) · Dana-Farber Cancer Institute (16) · City of Hope Medical Center (14) · First Affiliated Hospital of Zhejiang University (10) · Memorial Sloan Kettering Cancer Center (10) · German CLL Study Group (6) · St. Jude Children's Research Hospital (6) · AstraZeneca (5) · Beijing 302 Hospital (5) · Janssen Research & Development, LLC (5)
United States (434) · China (143) · France (95) · Australia (90) · Germany (86) · Spain (81) · Italy (71) · Canada (64) · United Kingdom (59) · Poland (38) · Belgium (37) · Netherlands (34) · Japan (33) · South Korea (33) · Czechia (31)
Courtney DiNardo, MD (6) · Hui Wei, MD (4) · Jianxiang Wang, Dr (4) · Nicholas Short (4) · Tapan M Kadia (4) · Xiaowen Tang, Ph.D (4) · Alessandra Ferrajoli, MD (3)
PMID 35829925, PMID 31023700, PMID 38620092, PMID 39368878, PMID 41671463, PMID 32786187, PMID 39133921, PMID 41843779, PMID 33394722, PMID 33795208, PMID 34255353, PMID 34398557, PMID 34534514, PMID 34608724, PMID 34614506, PMID 34634256, PMID 35046058, PMID 35063965, PMID 35405009, PMID 35704787, PMID 35708885, PMID 36007102, PMID 36892565, PMID 37093350, PMID 37315225, PMID 37703506, PMID 40226119, PMID 40513054, PMID 40913104, PMID 40944848, PMID 41269778, PMID 41796974, PMID 42419338, PMID 17038533, PMID 18596741, PMID 19151774, PMID 20564154, PMID 20602996, PMID 20668231, PMID 20876310, PMID 21459795, PMID 21654748, PMID 21680797, PMID 22564995, PMID 22855604, PMID 23432431, PMID 23733335, PMID 24062388, PMID 24639350, PMID 25047706
2023 (22), 2017 (14), P30CA033572 (13), 2016 (11), 2019 (11), 2018 (9), 2025 (8), 2014 (7), U10CA180820 (7), U10CA180888 (7), 2015 (6), U10CA180821 (5), UM1CA186689 (4), P30CA093373 (3), P30CA015083 (2)